A measure combining waist size and blood fats (CMI) predicts heart disease risk—but only up to a certain point; beyond that, higher values don’t mean higher risk.
Scientific Claim
The cardiometabolic index (CMI) is associated with a 27% higher hazard of incident cardiovascular disease in adults with cardiovascular-kidney-metabolic syndrome stages 0–3 after full adjustment, but its predictive relationship is nonlinear, with no increased risk above a threshold of 1.63.
Original Statement
“For CMI, a threshold was identified at 1.63. Above this value, no significant association with CVD risk was observed (HR = 0.95, 95% CIs: 0.84–1.06, P = 0.331). Below the threshold, however, each unit increase in CMI was significantly associated with elevated CVD risk (HR = 1.39, 95% CIs: 1.12–1.81, P < 0.001).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study used statistical modeling (RCS and two-piecewise Cox) to detect nonlinearity, and correctly reports hazard ratios with confidence intervals without implying causation.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether the CMI threshold of 1.63 for CVD risk is consistent across populations and ethnicities.
Whether the CMI threshold of 1.63 for CVD risk is consistent across populations and ethnicities.
What This Would Prove
Whether the CMI threshold of 1.63 for CVD risk is consistent across populations and ethnicities.
Ideal Study Design
A systematic review and meta-analysis of 10+ prospective cohorts (n>30,000) measuring CMI and incident CVD, using individual participant data to determine pooled threshold effects via spline modeling and stratified by ethnicity, sex, and diabetes status.
Limitation: Cannot determine if the threshold is causal or a statistical artifact of measurement error.
Prospective Cohort StudyLevel 2bWhether individuals above the CMI threshold of 1.63 have different biological pathways (e.g., inflammation, lipid metabolism) than those below it.
Whether individuals above the CMI threshold of 1.63 have different biological pathways (e.g., inflammation, lipid metabolism) than those below it.
What This Would Prove
Whether individuals above the CMI threshold of 1.63 have different biological pathways (e.g., inflammation, lipid metabolism) than those below it.
Ideal Study Design
A prospective cohort of 2,000 CKM stage 1–2 adults with CMI values above and below 1.63, followed for 5 years with serial measurements of inflammatory markers (IL-6, CRP), lipid profiles, and insulin resistance to compare metabolic trajectories.
Limitation: Cannot prove whether the threshold is biologically causal or merely a marker of disease progression.
Randomized Controlled TrialLevel 1bWhether targeting CMI reduction below 1.63 improves CVD outcomes compared to maintaining higher levels.
Whether targeting CMI reduction below 1.63 improves CVD outcomes compared to maintaining higher levels.
What This Would Prove
Whether targeting CMI reduction below 1.63 improves CVD outcomes compared to maintaining higher levels.
Ideal Study Design
A double-blind RCT of 800 adults with CMI >1.63, randomized to intensive lifestyle intervention (diet, exercise) to reduce CMI to <1.63 vs. standard care; primary outcome: composite CVD event over 3 years.
Limitation: Ethical and practical challenges in blinding and adherence to metabolic targets.
Cross-Sectional StudyLevel 4Whether CMI values above 1.63 correlate with reduced visceral fat or improved metabolic health markers.
Whether CMI values above 1.63 correlate with reduced visceral fat or improved metabolic health markers.
What This Would Prove
Whether CMI values above 1.63 correlate with reduced visceral fat or improved metabolic health markers.
Ideal Study Design
A cross-sectional study of 500 adults with CKM syndrome comparing visceral fat (MRI), liver fat (proton density fat fraction), and insulin sensitivity (HOMA-IR) between those with CMI <1.63 vs. ≥1.63.
Limitation: Cannot determine if the plateau reflects improved health or measurement saturation.
Evidence from Studies
Supporting (1)
This study found that a measure called CMI predicts heart disease risk in people with metabolic and kidney issues, and it shows that risk goes up by 27% until CMI hits 1.63—after that, it doesn’t get any higher. That’s exactly what the claim says.